|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
5.580 USD |
-3.46% | -0.18% | -22.61% | |
Published on 05/19/2025 at 07:45
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder |
07:45am |
RE |
|
Weight-loss drug developers line up to tap lucrative market as competition heats up |
May. 16 |
RE |
|
Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025 |
May. 13 |
|
|
Altimmune, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc. |
May. 13 |
CI |
|
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital |
May. 13 |
MT |
|
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital |
May. 13 |
RE |
|
Altimmune Q1 Net Income USD -19.575 Million |
May. 13 |
RE |
|
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 13 |
CI |
|
Altimmune, Inc. Secures Up to $100 Million in Credit Facility from Hercules Capital |
May. 13 |
CI |
|
Pfizer ends development of weight-loss pill danuglipron |
Apr. 14 |
RE |
|
OPKO and Entera partner to develop obesity pill |
Mar. 17 |
RE |
|
Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025 |
Mar. 13 |
RE |
|
Altimmune to test obesity drug for alcohol use disorder and related health conditions |
Mar. 13 |
RE |
|
Altimmune, Inc. Pursues Two Additional Indications for Its Lead Product Candidate, Pemvidutide |
Mar. 13 |
CI |
|
Altimmune, Inc. – Special Call |
Mar. 13 |
|
|
William Blair Initiates Altimmune at Market Perform |
Feb. 28 |
MT |
|
Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing |
Feb. 27 |
RE |
|
Altimmune, Inc., Q4 2024 Earnings Call, Feb 27, 2025 |
Feb. 27 |
|
|
Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026 |
Feb. 27 |
CI |
|
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
Altimmune, Inc. Announces Board Appointments |
Feb. 25 |
CI |
|
Fat, not muscle: drugmakers in race for next weight-loss breakthrough |
Feb. 19 |
RE |
|
Fat, not muscle: drugmakers in race for next weight-loss breakthrough |
Feb. 19 |
RE |
|
Stifel Initiates Altimmune at Buy With $18 Price Target |
Jan. 08 |
MT |
|
Altimmune, Inc.(NasdaqGM:ALT) added to NASDAQ Biotechnology Index |
Dec. 22 |
CI |
ALT: Dynamic Chart
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
More about the company
Buy
Average target price
20.56USD
Spread / Average Target
+268.38%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
